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ABSTRACT
Porcine contagious pleuropneumonia (PCP) is a serious respiratory disease in the pig industry. In the present study, 
candidate vaccines with broad-spectrum and disease-resistant effects were screened. The App lolA gene was amplified 
by PCR from the Actinobacillus pleuropneumoniae (App) serotype 1 genome. The bioinformatics analysis results 
revealed that the App lolA consisted of 633 bp, encoding 210 amino acid proteins. In addition, the App LolA shared 
a high sequence identity among the different App serotypes. In this study, the App lolA was inserted into pET32a (+). 
The recombinant protein LolA (rLolA) was produced in E. coli BL21 and then determined by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and a Western Blot process. Immune protective efficacy testing of 
the rLolA was performed in 4-week old BALA/c mice. The serum IgG levels were assayed using an enzyme-linked 
immune sorbent assay (ELISA) method. The results showed that the serum IgG levels of the mice in the experimental 
group were significantly higher than those in the Frund incompleted adjuvant (IFA) and saline immunization groups 
after the third immunization. In particular, significant differences in the high dose group (50 rLolA + IFA) (P<0.01). 50 
μg rLolA +IFA, 30 μg rLolA + IFA, 30 μg rLolA and 10 μg rLolA+ IFA treatments had induced 40%, 20%, 20%, 10% 
and 10% survival rates respectively. However, no mice had survived among the adjuvant group and saline groups. 
The 50 μg rLolA +IFA group displayed reductions in lung lesions. Therefore, it was ascertained from these results 
that the rLolA had induced partial immune protection in the experimental mice against App challenge infections. 
This study successfully accumulated data valuable for the future exploration of new vaccines for porcine contagious 
pleuropneumonia.
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considerable economic losses in the pig industry. 
PCP occurs in pigs of all ages, and is characterized 
by pulmonary fibrosis and hemorrhagic necrosis 
Introduction 
Porcine contagious pleuropneumonia (PCP), 
which is caused by App infection, is an extremely 
serious respiratory disease which leads to 
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(SASSU et al., 2017). PCP is mainly controlled 
by the optimization of management and housing 
conditions, along with antimicrobial therapy and 
vaccination measures (CHIErS et al., 2010). 
The currently available vaccines used for 
PCP are predominately traditional inactivated 
bacterins. However, they have been found to 
supply only partial protection against PCP, with a 
lack of cross-protection among the main serotypes 
(SASSU et al., 2017). It has been found that Apx 
exotoxins are major contributors to the virulence 
of App (CHIErS et al., 2010). Some previous 
studies have demonstrated that Apx toxins may 
potentially induce protective immunity, and have 
also displayed a wide range of cross-protective 
effects on a variety of serotypes (SASSU et al., 
2017). After immunization with Apx, the clinical 
manifestations of pleuropneumonia were observed 
to be improved, and the degrees of lung injuries 
were reduced (CHIErS et al., 1998; VAn and 
FREY, 2003; TUMAMAo et al., 2010). However, 
it has been found that subunit vaccines based on 
Apx cannot provide complete protection against 
pleuropneumonia infections (DEL et al., 2014). 
Along with App toxins, other important vaccine 
candidates include capsules, lipopolysaccharide 
(LPS), selective omps, transferrin binding proteins 
(Tbp), maltose inducible proteins, peptidoglycan-
associated lipo-proteins (PAIA), and outer 
membrane lipoprotein A (omlA) (MArTínEz-
MArTínEz et al., 2016; DEnEEr and PoTTEr, 
1989; FrEy et al., 1996; GErLACH et al., 1993). 
These have also been determined to induce partial 
immune-protective effects against App infections. 
In addition, they have also displayed the ability to 
improve the immune protective efficacy of ApxA 
exotoxins through fusion (ADkInS et al., 2012; 
TUMAMAo et al., 2010).
The omps of gram-negative bacterial pathogens 
are important functional proteins. They are known 
to be closely related to many functions, such as the 
maintenance of the outer membrane structures of 
bacteria, transport of bacterial cell substrate, and 
the pathogenesis of bacteria (PATEL et al., 2017). 
Due to the fact that the Omps are located on the 
surface of bacterial cells, they are susceptible to 
attacks by antibodies, which in turn induces immune 
protection. Furthermore, highly conserved omps 
could potentially induce cross-protection effects 
against pathogen infections (GUo et al., 2017). 
It has been documented previously that the Omps 
of Salmonella typhimurium can induce immune 
protection against infection in mice (ISIBASI et 
al., 1988). Pasteurella multocida (Pm) Omps have 
also displayed good immunogenicity (kUMAr et 
al., 2013). In previous studies, the immunization 
of mice with romp87 resulted in increased antigen 
specific IgG titres in serum, and provided protection 
ratings of 66.6% and 83.3% following homologous 
and heterologous challenges, respectively 
(kUMAr et al., 2013). The accumulation data also 
revealed that the App omps had provided protective 
effects against App infections (LIAo et al., 2009). 
Meanwhile, the incidence rates and lung lesions 
were found to be reduced under other serotype 
infection conditions (HU et al., 2015; CHEn et 
al., 2012; VAn and FREY, 2003). In the present 
study, the highly conserved omp protein LolA was 
identified by analyzing the App genome. The aim 
of the present study was to investigate the immune 
protective efficacy of the recombinant LolA (rLolA) 
using a mouse model. 
Materials and methods
Bacterial strains and growth conditions. 
In present study, App Serotype I strains were 
inoculated onto a Tryptic Soy Broth (TSB, Beijing 
Luqiao Technology Co., Ltd. China) solid medium, 
containing 5% Mycoplasma free neonatal Cattle 
Serum (Beijing Luqiao Technology Co., Ltd. 
China) and 10 μg/mL of nAD (Beijing Dingguo 
Biotechnology Co., Ltd. China), and maintained 
at 37 °C overnight. A single colony was selected 
and inoculated into the TSB liquid medium for six 
hours at 37 °C on a shaker. Then, the bacteria were 
collected by centrifugation at 5,000 g.
Cloning and bioinformatics analysis of App 
lolA gene. The primer pairs (forward primer F1: 
ATTGTCCCAAGAGTATAA and reverse primer 
r1: CTAATGTGTTTACTGATT) were designed 
on the basis of some sequences of the App lolA 
gene publicly available in the GenBank. In this 
study, the App lolA gene was amplified from the 
App serotype I genome via PCr. The PCr reaction 
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conditions were as follows: Initial denaturation at 
95 ℃ for three minutes; followed by 30 cycles of 
denaturation at 94 ℃ for 50 seconds, annealing at 55 
℃ for 30 seconds, extension at 72 ℃ for 45 seconds 
and a final extension at 72 ℃ for ten minutes. The 
PCR product was detected using an agarose gel 
electrophoresis method, and then sequenced by 
Shanghai Biological Engineering Co. Ltd. (China). 
An open reading frame (orF) analysis was 
performed using orF finder software. The signal 
peptide sequence of the protein was analyzed using 
a SinalP 4.1 server. The transmembrane region of 
the protein was analyzed using a TMHMM server, 
version 2.0. The results of the amino acid sequence 
alignment analysis of LolA in this study, along with 
others downloaded from GenBank, were analyzed 
using DnAMAn software.
B-cell epitopes prediction of App LolA. B-cell 
epitope predictions of the App LolA were obtained 
using online software, namely, the process was 
first completed using ABCpred (http://www.
imtech.res.i-n/raghava/abcpred), and confirmed by 
CoBEPro (http://scratch.proteomics.ics.uci.edu), 
BepiPred-2.0 (http://www.cbs.dtu.dk/services/ 
BepiPred/), and Vaxipred (http://www.Imtech.r-es.
in/raghava/bcepred/). Then, Vaxipred was used for 
analysis of the hydrophilicity, plasticity, and surface 
accessibility of the App LolA.
Construction of the recombinant plasmids. 
The App lolA coding sequence (not including 
the signal peptide sequence) was amplified by 
PCr. The primer pairs were: F2: 5' CGCGGA-
TCCGCGATAGTATCGTCCAA CCGCTTAG 3' 
(BamHⅠ), and r2: 5'CCCAAGCTTGGGAAAC-
CAGACCGCTTCATTC GTC 3' (Hind Ⅲ). 
The PCr conditions were as follows: Initial 
denaturation at 95 oC for three minutes; followed 
by 30 cycles of denaturation at 94oC for 50 seconds, 
annealing at 55 o C for 30 seconds, extension at 72o 
C for 45 seconds and a final extension at 72 o C 
for ten minutes. Following the completion of the 
purification process, the PCr product and pET 
32(a) vector were digested with BamHI and Hind 
Ⅲ (Takara Co., Ltd. China), and then ligated with 
T4 DnA ligase (Takara Co., Ltd. China). At that 
point in this study the recombinant plasmid pET32-
LolA was transformed into competent cells of E. 
coli BL21 (DE23) using a heat shock method. The 
recombinant clones were selected on Luria Broth 
(LB) agar containing ampicillin (100 μg/mL). The 
recombinant plasmid pET32-LolA was verified by 
the restriction enzyme digestion and nucleotide 
sequence analysis methods (HU et al., 2017).
Expression and purification of recombinant 
proteins. The E. coli BL21 cells carrying pET32- 
lolA were grown in Luria Broth (LB), supplemented 
with 100 μg ampicillin/mL. Then, the recombinant 
clones at the mid-log phase were induced with 
a final concentration of 1 mM of isopropyl-β-D-
galactopyranoside (Sigma, China) for a three- hour 
period prior to harvesting the cells. The selected 
cells were washed twice with phosphate-buffered 
saline (PBS) pH 7.2 solution and resuspended 
in PBS at a ratio of 1:20 of the original culture 
volume. The cells were disrupted using a CP70T 
Ultrasonic Processor (Cole-Parmer, USA) for 6 
to 10 seconds at 60% amplitude. The cell lysates 
were harvested and washed twice with PBS. The 
recombinant proteins were purified using 8 mol/L 
urea and maintained at -20 °C for future use. The 
purified proteins were determined using SDS-
PAGE and Western Blot methods (HU et al., 2017).
Western Blot analysis results. In the present 
study, the recombinant proteins were first run on a 
10% SDS-polyacrylamide gel and then transferred 
to nitrocellulose membranes using a semi-dry 
blotting system (Beijing Liuyi Co., Ltd., China). 
Each lane was separated by cutting the nitrocellulose 
membrane. The primary antibodies were murine 
normal serum and App-infected murine serum, 
respectively. Western Blot analysis was carried 
out using the respective primary antibodies at a 
dilution rate of 1:200. In addition, goat anti-mouse 
IgG conjugated to horseradish peroxidase (HrP) 
(Sigma, China) was used as the secondary antibody 
at a dilution rate of 1:10,000. DAB was used for 
color detection and a pre-stained protein Marker 
10-250kD (Beijing Quantum Biotechnology Co., 
Ltd. China) was used as the size marker (HU et al., 
2017).
Immunization and challenge experiments. In 
the current study’s experiments, 60 four-week old 
female BALB/c mice, weighing between 16 and 18 
g were randomly divided into six groups of 10 mice 
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each. The mice in four of the experimental groups 
were respectively subcutaneously (SC) inoculated 
with a low-dosage adjuvant (Freund's incomplete 
adjuvant+ 10 μg rLolA); medium-dosage adjuvant 
(Freund's incomplete adjuvant+ 30 μg rLolA); high-
dosage adjuvant (Freund's incomplete adjuvant+ 50 
μg rLolA); and medium-dosage (30 μg rLolA) at 
weeks 0, 2, and 4. The Freund's incomplete adjuvant 
was purchased from Beijing Solarsoft Technology 
Co., Ltd. (China). The mice in the remaining two 
parallel control groups were subcutaneously (SC) 
injected with normal saline and Freund's incomplete 
adjuvant, respectively. Then, the mice were 
intraperitoneally challenged with 10 × LD50 App at 
two weeks after the third immunization process. The 
survival rates were calculated post-infection with 
the survival rate equaling the number of survivors/
number of animals used in the experiments, times 
the percentage of survivors. The mice were tail 
bled on the first day and again at one day prior to 
both booster vaccinations and challenges (weeks 0, 
2, 4, and 6, respectively). The sera were stored at 
-20℃ for further use. All the animal experiments 
in this study were performed with the approval of 
the Ethics Committee on Animal Experimentation 
of Hunan Agricultural University (HU et al., 2017).
 Determination of the antibody responses to 
the vaccine formulations. The IgG titers of the 
specific antibody responses in the murine sera were 
determined using an enzyme-linked immunosorbent 
(ELISA) assay method. In summary, 96-well 
polystyrene microtiter plates were coated with 
purified rLolA (10 μg/well), and then incubated 
overnight at 4℃. After three washes with PBST, the 
plates were blocked by incubation with a blocking 
solution (1% BSA in PBS) for two hours at 37 ℃. 
After the plate was washed again, 100 μL of the 
diluted murine serum (1:4000) was added to each 
well followed by an incubation period of two hours 
at 37 ℃. Then, rabbit anti-mouse IgG conjugated to 
horseradish peroxidase (HrP) (Sigma, China) was 
used as a secondary antibody (100 μL /well) at a 
dilution rate of 1:4000, and incubated for two hours 
at 37 ℃. At this point in the experiment, TMB 
(3.3.5.5-Tetramethylbenzidine, Beijing Dingguo 
Biotechnology Co., Ltd. China) was adopted as the 
colorimetric reagent. The reactions was terminated 
by adding 100 μL of 2 mol/L H2SO4. The plates 
were read at 450 nm on a microtiter plate reader, 
in order to determine optical density (oD). All the 
assays were performed in triplicate. 
Statistical analysis results. Statistical analyses 
were performed in the present study using SPSS 
software. The data were expressed as the mean ± 
SD, and a P value of less than 0.05 was considered 
to be statistically significant.
Results
Cloning and analysis of the App lolA gene. The 
PCr product of the App lolA gene was detected and 
appeared at approximately 750 bp on agarose gel 
electrophoresis, as detailed in Fig. 1. 
Fig. 1. Electrophoretic map of Lola PCr product. M - 
DnA Marker; 1 - Lola PCR product
After the sequence was sequenced, it was found 
that the App lolA gene (Bankit 2090091) contained 
a coding nucleotide sequence of 633 bp in length, 
which encoded an outer membrane protein of 210 
amino acids. The theoretical molecular weight and 
pI of the App LolA were 2,3458 dalton and 9.70, 
respectively. The results of this study’s multiple 
sequence alignment analysis indicated that the amino 
acid sequence displayed higher than 99% identity 
with the different App serotypes in GenBank (App 
ser 1 str. 4074 AWG94892.1; App ser 2 str. 4226 
EFL79115.1; App ser 3 str. JL03 WP_012262832.1; 
App ser 4 str. M62 EFM90298.1; App ser 5b str. 
L20 A3MzJ2.1; App ser 6 str. Femo EFL81040.1; 
App ser 7 B3GX52.1; App ser 8 CUU51798.1; App 
Y. Zhang et al.: The immune protective efficacy of recombinant outer - membrane protein LolA from  
Actinobacillus pleuropneumoniae in mice
Vet. arhiv 90 (3), 279-287, 2020 283
ser 9 WP_005609863.1; App ser 10 str. D13039 
EFM96841.1; App ser 11 str. 56153 EFM98933.1; 
App ser 12 str. 1096 EFn01056.1; and App ser 13 
str. n273 EFn03227.1). These findings suggest 
that the App LolA protein was highly conserved 
among the App strains, with the potential to induce 
a cross-protective effect against App. In addition, 
using in-silico analysis methods (the web server 
ABCpred, CoBEPro and BepiPred-2.0), along with 
hydrophilicity, accessibility and plasticity analysis 
processes, it was also found that three linear B cell 
epitopes could potentially be identified in the 59-
65, 170-175, and 198-202 amino acid regions of the 
App LolA (Table 1). 
Table 1. The putative B cell epitopes of App LolA 
protein




Fig. 2. SDS-PAGE analysis of rLoLA. M - protein 
Marker; 1 - recombinant bacteria with IPTG induction; 
2 - Purfied rLoLA; 3 - recombinant bacteria without 
IPTG induction
SDS-PAGE and Western Blot determinations 
of the rLolA. In the present study, the recombinant 
protein from the E. coli BL21 cells carrying pET32- 
LolA, which contained the coding sequences of the 
App lolaA gene, was detected in the cell lysates 
and purified products. As detailed in Fig. 2, these 
appeared at approximately 28 kDa ( a protein with 
some tag sequences in pET-32(a)) on the SDS-PAGE 
gel. This suggested that the rLolA was successfully 
produced by the E. coli BL21 harboring the pET32- 
LolA with the lolA gene inserted. In regard to the 
results of this study’s Western Blot analysis of the 
App infected murine sera, it was found that the 
serum of the App infected mice reacted with the 
purified recombinant protein, which indicated that 
the rLolA displayed a good immunogenicity effect 
(Fig. 3).
Fig.3. Western blot detection of rLoLA. M - Protein 
standard Maker; 1 - Determination of positive sera of 
infected- mice by App; 2 - Determination of negative 
sera of normal mice
Immune responses against rLolA proteins and 
their protective efficacy. In this study, the BALB/c 
mice were inoculated subcutaneously three times. 
The sera were collected at day 0, and again prior to 
both the inoculations and the challenges (days 14 
and 28, respectively), and utilized for measurements 
of the IgG titers. 
As shown in Fig. 4, the serum IgG levels in 
the mice which had been vaccinated with rLolA 
+ adjuvant were significant. In particular, in the 
high dosage group (50 μg + adjuvant) (P<0.01), 
the levels had noticeably increased after the second 
immunization. Then, on the fourth day of the App 
infection, the protective efficacy of the rLolA 
proteins was observed. The experimental results 
showed that the vaccine formulations composed 
of Freund's incomplete adjuvant + 50 μg rLolA, 
Freund's incomplete adjuvant + 30 μg rLolA, 
Freund's incomplete adjuvant + 10 μg rLolA, and 
the 30 μg rLolA had conferred 40%, 20%, 10%, 
and 20% protection rates in the mice, respectively. 
The differences in the protection rates between 
the immunized group and the control group 
(adjuvant group and saline group) were found to be 
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significant. It was observed that all the control mice 
had died. The lungs of the mice immunized with 
Freund's incomplete adjuvant+ 50 μg rLolA showed 
reductions in lung lesions when compared with the 
mice of the other immunized groups. The clinical 
condition of the surviving mice gradually returned 
to normal and they began to eat again. These results 
indicated that the subcutaneous injections of rLolA 
had induced immune responses and partial immune 
protection in the mice examined in this study’s 
experiments.
Fig. 4. Level of antibody IgG against rLoLA before/after immunization and infection
note: Medium dosage: 30 μg rLoLA; Low dosage +adjuvant: 10 μg rLoLA+ IFA; Medium dosage +adjuvant: 30 μg rLoLA + 
IFA; High dosage + adjuvant: 50 μg rLoLA +IFA; ** indicted very significant difference (experimental groups vs control groups, 
P<0.01)
Discussion
In this study, the results of the bioinformatics 
analysis showed that the App LolA was a 
transmembrane binding protein with 211 amino 
acids, and had high identity among the different 
serotypes of App. It also showed that this protein 
contained three linear B cell epitopes. The West Blot 
results indicated that the rLolA had reacted with the 
positive sera of App-infected mice. These findings 
suggested that App LolA had an immunogenicity 
effect and could potentially induce cross-protection 
against different App serotypes. 
Bacterial LolA is a peripheral protein which 
plays an important role in the sorting and 
outer membrane localization of lipoproteins in 
bacteria (züCkErT, 2014; GrABoWICz and 
SILHAVy, 2017). Lipoproteins are anchored to 
the periplasmic sides of either the inner or outer 
membranes. Following their expressions in cells, 
they must be sorted and located into the inner or 
outer membranes by other protein complexes. It has 
been reported that five Lol proteins are involved 
in the sorting and outer membrane localization 
of lipoproteins (nArITA and TokUDA, 2010). 
LolCDE is composed of one copy each of the 
membrane subunits LolC and LolE, and two copies 
of the nucleotide-binding subunit LolD (yASUDA 
et al., 2009). It is an ATP binding cassette (ABC) 
transporter which releases outer membrane-
directed lipoproteins from the inner membrane 
in an ATP-dependent manner. This subsequently 
leads to the formation of a water-soluble complex 
between the lipoprotein and LolA (rEMAnS et 
al., 2010). The LolA-lipoprotein complex crosses 
the periplasm and then interacts with the outer 
membrane receptor LolB. This is known to be 
essential for the anchoring of the lipoproteins to 
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the outer membranes (CoLLIn et al., 2011). 
Previous research results regarding uropathogenic 
Escherichia coli (UPEC) revealed that the lolA 
were poorly expressed in vitro (in human urine or 
LB medium), yet highly expressed in vivo. It was 
observed that LolA could potentially react with 
UPEC-infected mouse sera, demonstrating good 
immunogenicity. Therefore, they could be useful as 
potential vaccine targets (VIGIL et al., 2011). In 
this study, it was found that the levels of serum IgG 
antibodies increased significantly in the mice after 
the third immunization in the recombinant protein 
rLolA and rLolA+ adjuvant groups. It was found 
that the rLolA and rLolA+ adjuvant had the ability 
to induce survival rates between 10% and 40%, 
respectively, in the examined mice.
Some previous research studies regarding App 
Omps as vaccine candidates have been reported. 
The results of Immunoproteomic analyses of 
omps confirmed that the App omp displayed 
good immunogenicity effects (LIAo et al., 2009). 
In ADDITIon, Vaccination procedures using 
Apx/rApx pluse omps were determined to have 
the potential to both increase protection and 
significantly reduce lung lesions in mice and pigs 
(WAnG et al., 2009; DEL et al., 2014; WAnG et 
al., 2006). Meanwhile, this type of formula could 
also induce a cross reaction against different App 
serotypes (DEL et al., 2014). In this study, it was 
confirmed that the mice immunized with 50 μg 
rLolA+ adjuvant showed a reduction in lung 
lesions when compared with the mice in the other 
immunized groups. 
As mentioned in the above results, this study 
accumulated basic data for further exploration 
of new vaccines against porcine infectious 
pleuropneumonia.
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SAžeTAK
zarazna pleuropneumonija svinja (PCP) teška je respiratorna bolest u svinjogojskoj industriji. U ovom su 
istraživanju analizirana kandidatna cjepiva širokog spektra i njihova učinkovitost u otpornosti na tu bolest. Gen App 
lolA umnožen je PCr-om od genoma serotipa 1 Actinobacillus pleuropneumoniae (App). rezultati bioinformatičke 
analize pokazali su da se App lolA sastoji od 633 bp, kodirajući 210 aminokiselinskih proteina. Također, App LolA 
dijeli visoki stupanj prepoznatljivosti sekvenci među različitim serotipovima App. U ovom je istraživanju App lolA 
umetnut u pET32a (+) plazmid. rekombinantni protein LolA rLolA je proizveden u E. coli BL21 i zatim određen 
poliakrilamidnom (SDS-PAGE) gel-elektroforezom i western blot metodom. Testiranje imunozaštitnog djelovanja 
rLolA provedeno je u miševa BALA/c starih četiri tjedna. Serumske razine IgG analizirane su primjenom metode 
ELISA. rezultati su pokazali znakovito više serumske razine IgG-a u miševa u eksperimentalnoj skupini od onih u 
skupini s adjuvansom (IFA) i skupini sa soli  nakon treće imunizacije. navedeno posebno vrijedi za znakovite razlike 
u skupini sa visokim dozama (50 rLolA + IFA) (P < 0,01).Stope preživljavanja po skupinama iznosile su  40 % (50 μg 
rLolA + IFA), 20 % (30 μg rLolA + IFA), 20 % (30 μg rLolA) and 10 % (10 μg rLolA+ IFA). U skupinama u kojima 
je imunizacija provedena s adjuvansom i solju nije bilo preživjelih miševa. Skupina 50 μg rLolA + IFA pokazala je 
smanjenje plućnih lezija. rezultati ovoga istraživanja upućuju da je rLolA izazvao djelomičnu imunosnu zaštitu od 
infekcija izazvanih App-om u pokusnih miševa i kao takvi daju doprinos za buduća istraživanja cjepiva protiv zarazne 
pleuropneumonije svinja.
Ključne riječi: Actinobacillus pleuropneumoniae; gen lolA; rekombinantni LolA; učinkovitost imunozaštite_____________________________________________________________________________________________

